Kinetolab

team of
professionals:
this is KIneto lab

Our mission is to enhance the quality of drug discovery and developmental concept of our partners using scientifically founded strategies and provide high quality services, in order to reach the clinical stage faster and with higher reliability

we manage

the whole process of drug development from target identification and validation through high throughput in vitro screenings to in vivo animal model studies

we grow
our biobank of PDTX models to provide a more sophisticated platform to our partners, offering clinically relevant models, improving the reliability of translational research
we develop

wide range of preclinical models, originated from human (xenograft) or murine (allo-/iso-graft) tumor cell lines, for testing various anticancer strategies and treatments

History

15 years of experience in cancer research.
KINETO Lab is a privately owned biotechnology research and CRO company based in Budapest, Hungary.

15 years of experience in cancer research. KINETO Lab is a privately owned biotechnology research and CRO company based in Budapest, Hungary.

company Establishment

Two of founders, Attila Kigyós and József Tóvári are the owners and are working for the company

20
07

“Magicbullet” consortium

KINETO Lab Ltd. participating in Horizon 2020 Marie Skłodowska-Curie Actions “Magicbullet” consortium

read more

20
15

endothelial markers

Tumor endothelial cell
research launched

read more

20
17

PDTX biobank

First PDTX models established, PDTX biobank launched

read more

20
19

NEW KRAS CONSORTIUM

The Company joined the Hungarian new KRAS consortium

read more

20
21

BIOSMALL CONSORTIUM

KINETO Lab Ltd. participating in Horizon
2020 Marie Skłodowska-Curie
“BIOSMALL” consortium

read more

20
23

20
10

CD34 antibody

First own CD34 antibody developed

read more

20
16

KRAS consortium

The Company joined the Hungarian KRAS consortium (RASopathies)

read more

20
18

“Magicbullet::Reloaded”

KINETO Lab Ltd. participating in Horizon 2020 Marie Skłodowska-Curie Actions “Magicbullet::Reloaded” consortium

read more

20
20

related PhD work

Our work on endothelial cells reinforced by the company’s first related PhD research

read more

20
22

NEXGEN CONSORTIUM

KINETO Lab Ltd. participating in HORIZON-HLTH to develop the Next generation vaccine platform for the treatment of Parkinson’s disease

read more

company Establishment

Two of founders, Attila Kigyós and József Tóvári are the owners and are working for the company

20
07

CD34 antibody

First own CD34 antibody developed

read more

20
10

“Magicbullet” consortium

KINETO Lab Ltd. participating in Horizon 2020 Marie Skłodowska-Curie Actions “Magicbullet” consortium

read more

20
15

KRAS consortium

The Company joined the Hungarian KRAS consortium (RASopathies)

read more

20
16

endothelial markers

Tumor endothelial cell
research launched

read more

20
17

“Magicbullet: :Reloaded”

KINETO Lab Ltd. participating in Horizon 2020 Marie Skłodowska-Curie Actions “Magicbullet::Reloaded” consortium

read more

20
18

PDTX biobank

First PDTX models established, PDTX biobank launched

read more

20
19

related PhD work

Our work on endothelial cells reinforced by the company’s first related PhD research

read more

20
20

NEW KRAS CONSORTIUM

The Company joined the Hungarian new KRAS consortium

read more

20
21

NEXGEN CONSORTIUM

KINETO Lab Ltd. participating in HORIZON-HLTH to develop the Next generation vaccine platform for the treatment of Parkinson’s disease

read more

20
22

BIOSMALL CONSORTIUM

KINETO Lab Ltd. participating in Horizon 2020 Marie Skłodowska-Curie “BIOSMALL” consortium

read more

20
23

MANAGEMENT

Acknowledged experts providing tailored approaches for successful and effective research and development. Giving in our hands your concept guarantee you high quality investigation.

Attila Kigyós

founder and CEO KINETO Lab

«Drug development today requires effective collaboration between different disciplines. I consider it very important that our company excels in coordinating the work of chemists, biologists and statisticians. Therefore, I can confidently recommend our services to chemical researchers developing drugs, not only in the testing of their drug candidates, but also in the planning phase of the project.»

trust.
efficiency.
knowledge.

Attila Kigyós

MSc, Chief Executive Officer

József Tóvári

PhD, Chief Scientific Officer

Mihály Cserepes

PhD, Project Manager

Ivan Ranđelović

PhD, Project Manager

Attila Kigyós

MSc, Chief Executive Officer

Attila Kigyós, MSc, is the founder and CEO of KINETO Lab Research and Development Ltd. In addition to his role as Managing Director of the company, Attila has more than two decades of experience in the fields of informatics, biotechnology and drug discovery screening.

Attila was appointed for CEO based on his leadership experience in managing Hungarian biotech companies and his strong leadership and personal qualities.

József Tóvári

PhD, Chief Scientific Officer

József Tóvári, PhD, is the founder and CSO of KINETO Lab Research and Development Ltd., head of the Department of Experimental Pharmacology, National Institute of Oncology, Budapest.
Dr. Tóvari has a strong scientific experience in the field of translational applied research and development in oncology. He is co-author of 120 scientific publications; his cumulative impact factor is >500. He has >2800 independent citations.

Mihály Cserepes

PhD, Project Manager

Mihály is a postdoctoral biologist researcher and project manager in KINETO Lab, focusing his work on Patient-derived xenograft models, primary tumor cell line establishment and antibody development, as well as in vivo experiment planning and supervision.

Mihály is author of 13 peer-reviewed articles, with the total impact factor of 82.2, and 247 citations (as of February, 2023). He attended to more than 15 scientific conferences, earning two prizes for best poster.

Ivan Ranđelović

PhD, Project Manager

Ivan Ranđelović , PhD, is postdoctoral biologist researcher and project manager in KINETO Lab, focusing on drug discovery and preclinical investigation and development of targeting cancer therapeutics. Ivan is also responsible for the marketing and international relations of the company.

Ivan is author of 16 articles published in international peer-reviewed journals with a total impact factor of 64.1 which independently were cited over 100 times. He represented his work on numerous scientific conferences, where earned one prize for the best poster.

trust.
efficiency.
knowledge.

Attila Kigyós

Chief Executive Officer

Attila Kigyós, MSc, is the founder and CEO of KINETO Lab Research and Development Ltd. In addition to his role as Managing Director of the company, Attila has more than two decades of experience in the fields of informatics, biotechnology and drug discovery screening.

Attila was appointed for CEO based on his leadership experience in managing Hungarian biotech companies and his strong leadership and personal qualities.

József Tóvári

Chief Scientific Officer

József Tóvári, PhD, is the founder and CSO of KINETO Lab Research and Development Ltd., head of the Department of Experimental Pharmacology, National Institute of Oncology, Budapest.
Dr. Tóvari has a strong scientific experience in the field of translational applied research and development in oncology. He is co-author of 120 scientific publications; his cumulative impact factor is >500. He has >2800 independent citations.

Mihály Cserepes

PhD, Project Manager

Mihály is a postdoctoral biologist researcher and project manager in KINETO Lab, focusing his work on Patient-derived xenograft models, primary tumor cell line establishment and antibody development, as well as in vivo experiment planning and supervision.

Mihály is author of 13 peer-reviewed articles, with the total impact factor of 82.2, and 247 citations (as of February, 2023). He attended to more than 15 scientific conferences, earning two prizes for best poster.

Ivan Ranđelović

PhD, Project Manager

Ivan Ranđelović, PhD, is postdoctoral biologist researcher and project manager in KINETO Lab, focusing on drug discovery and preclinical investigation and development of targeting cancer therapeutics. Ivan is also responsible for the marketing and international relations of the company.

Ivan is author of 16 articles published in international peer-reviewed journals with a total impact factor of 64.1 which independently were cited over 100 times. He represented his work on numerous scientific conferences, where earned one prize for the best poster.

publications

PDTX

Evolving Acquired Vemurafenib Resistance in a BRAF V600E Mutant Melanoma PDTX Model to Reveal New Potential Targets.
Tóvári J, Vári-Mező D, Surguta SE, Ladányi A, Kigyós A, Cserepes M. Cells. 2023, 12(14), 1919.

PEPTIDE-DRUG CONJUGATES

Optimizing the Enzymatic Release of MMAE from isoDGR-based Small Molecule Drug Conjugate by Incorporation of a GPLG-PABC Enzymatically Cleavable Linker.
Zambra M, Ranđelović I, Talarico F, Borbély A, Svajda L, Tóvári J, Mező G, Bodero L, Colombo S, Arrigoni F, Fasola E, Gazzola S, Piarulli U. Front Pharmacol. 2023, 14:1215694.

KRAS TARGETING - FRAGMENT SCREENING

Activation-Free Sulfonyl Fluoride Probes for Fragment Screening.
Petri L, Ábrányi-Balogh P, Csorba N, Keeley A, Simon J, Ranđelović I, Tóvári J, Schlosser G, Szabó D, Drahos L, Keserű GM. Molecules. 2023, 28(7):3042.

we Develop PDTX models resembling tumor heterogeneity and tumor microenvironment for better predictability of clinical therapeutic response

FACILITIES

We have licensed laboratory fully equipped with instruments for in vitro cell-based analysis and for molecular biology techniques, histochemical and patological studies. As well there is animal house for conducting animal experiments, with all official and ethical approvals.

technology

for histochemical & pathological studies

SPF

animal house

IVIS

in vivo imaging system

EQUIPPED

for cell culturing & molecular biology studies

05/01/2024

Attending NEXGEN-PD consortium meeting on January 11th to 12th, 2024 in Salzburg, Austria

read more

25/10/2023

BIOSMALL consortium kick off meeting was held on October 20th 2023 in Vienna, Austria

read more

03/08/2023

Lecture at International Conference on “Drug Conjugates for Directed Therapy”, from August 23rd to 25th, 2023, at Technical University of Darmstadt, Darmstadt, Germany

read more

CONTACTS

If you have any question regarding our research, services or PDTX models, and if you want to get in touch with us, fill the form or send us an e-mail on info@kinetolab.hu.

We are always open for your CV and application in case you would like to work in an innovative, dynamically growing cancer research-related biotech company in the future. If you think you could fit in KINETO Lab’s team, please contact us.